++++++AIDS Medikament +++++ - 500 Beiträge pro Seite

[109]

Immune Response hat klinischen Versuch in Thailand
positiv abgeschlossen !!
Könnte Durchbruch bedeuten !!
weitere Infos folgen.

[guenthi]

Danke für deine Info, weißt du die WKN ?

[Aktienmogul]

Hier die WKN: 879428!

schon 55% in FSE!


cya

[Klaus Meier]

dort wird es wohl viele freiwillige zum testen gehen

[109]

Hier die Pressemitteilung.


Recent Clinical Data Suggest That REMUNE(TM) May Help to Rebuild Immune System When Used Alone or in Combination With Antiviral Drugs Against AIDS Virus
Thursday, March 23, 2000 07:01 AM Mail this article to a friend

Thai Investigators to Propose REMUNE Monotherapy As First Course of Treatment in HIV-Infected Individuals in Thailand
CARLSBAD, Calif., March 23 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR, news, msgs) announced today that recent clinical data suggest that REMUNE(TM), its immune-based therapy to treat HIV infection, may induce HIV immunity when used as a combination therapy with other antiviral drugs or when used alone as a monotherapy. The data from multiple clinical trials were presented at "An International Conference on HIV Vaccines -- An Annual Update -- 2000" sponsored by the Thai Ministry of Public Health in Bangkok, Thailand.

Data were presented by Drs. Vernon Maino of Becton Dickinson, Fred Valentine of New York University, Frances Gotch of Chelsea and Westminster Hospital in London, Ron Moss of The Immune Response Corporation and Vina Churdboonchart and Wisut Sukeepaisarncharoen of Thailand, all investigators of clinical trials that examined the effects of REMUNE in HIV-infected patients. An observation common to the multiple trials suggest that patients treated with REMUNE in combination with antiviral drug therapy mount strong CD4 helper T cell immune responses against HIV.

Data from the double-blind, placebo controlled study in Thailand, in which REMUNE was examined as a monotherapy, were presented by Drs. Vina Churdboonchart and Wisut Sukeepaisarncharoen. In this study, 297 HIV-1 infected patients who had never taken antiviral drug therapy received either REMUNE or placebo during the 40-week trial period and were monitored for several indicators of immune health and disease progression. The primary measure of the number of CD4 helper T cells was significantly higher (p<0.05) in the REMUNE treatment group. Furthermore, delayed type hypersensitivity (DTH) skin tests and Western blots (test that detects antibodies against HIV) performed on a random, pre-selected subset of patients indicated that HIV-specific immunity was favored in patients treated with REMUNE (p<0.05).

"While antiviral drug therapy has been very beneficial to HIV patients in keeping viral load in check, it has not generally proven to help rebuild the immune system, which is ravaged by the virus. A common theme among the trial results reported today suggests that REMUNE may help to restore immune function to these patients. In fact, it is the T helper cells -- the very immune cells that are destroyed by the virus -- that appear to re-establish after treatment with REMUNE," said Dr. Vina Churdboonchart, principal investigator for the trial in Thailand. "This is important because an emerging consensus among HIV researchers is that immune health may be the key to controlling HIV infection in the long term." Dr. Churdboonchart stated that she is currently completing all documentation necessary for submission to the Thai Minister of Public Health for commercial approval of REMUNE in Thailand.

Dr. Sukeepaisarncharoen, a clinician in the Thai study, presented data obtained during the follow-up period after the trial was completed on the same subset of patients. He noted that 87% (59/68) of those patients tested 48 weeks after the trial`s end had stable (39 patients) or significantly decreased (20 patients) amounts of HIV in the bloodstream, commonly referred to as viral load. Furthermore, the decrease or stabilization of viral load was associated with a sustained increase in number of CD4 helper T cells as well as increased body weight.

"Several clinical parameters of immune health and disease progression assessed in this trial and during the follow-up period suggest that REMUNE alone may be a beneficial monotherapy in the treatment of HIV infection. This is particularly important for HIV patients who do not have access to antiviral drug therapy," said Dr. Churdboonchart who indicated that based on these and previous results submitted to the Thai Ministry of Public Health, the Thai investigators will propose that REMUNE monotherapy be administered to HIV-infected individuals in Thailand as a first course of treatment.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV and autoimmune diseases. In addition, the Company is working on cancer vaccines and gene therapy.

NOTE: News releases are available through PR Newswire Company News On- Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including, but not limited to, its report on Form 10-K for the year ended December 31, 1998 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. REMUNE(TM) is a trademark of The Immune Response Corporation.

SOURCE The Immune Response Corporation

CONTACT: Kathy Lane of The Immune Response Corporation, 760-771-2236


Quote for referenced ticker symbols: IMNR

© 2000, PR Newswire

[109]

Immune Response is a development-stage company whose primary project is an injectable immune-based therapy called REMUNE, which is designed to slow or stop the progression of HIV infections into AIDS. The company is also developing and testing therapeutic products for other autoimmune conditions -- psoriasis, rheumatoid arthritis, multiple sclerosis, and some types of cancer. Immune Response is developing a technology to deliver gene therapy to liver cells as a treatment for such diseases as hemophilia A and hepatitis B. REMUNE is in Phase III clinical trials for FDA approval; Agouron Pharmaceuticals has agreed to market the drug. Other treatments are also in testing, but none have yet been brought to market.

5935 Darwin Ct.
Carlsbad, CA 92008
760-431-7080
http://www.imnr.com
CEO: Dennis J. Carlo
CFO: Howard Sampson
HR: Lisa Gonzalez
Employees: 156
Fiscal Year End: December
1999 Sales ($ Mil.): $20.8
1-Yr Sales Change: 17.5%
Net Income ($ Mil.): ($15.0)
Ticker Symbol: IMNR
Exchange: Nasdaq
ny Info

[Biotechguru]

Biotech-STAR: STRESSGEN


http://www.stressgen.com/

-Vorschungsvorschsprung im Bereich der Stressproteine >> Marktführer

-Etablierter Zulieferer für Pharmaunternehmen >> Beziehung zu Großkonzernen der Pharmabranche

-Billige Einstiegskurse: Jetzt

- Geringe Marktkapitalisierung: ~270 Mio Euro
-Kaufempfehlung von Global Biotech Investing, kurz vor dem Biotechcrash : 300%
>> Forschungs Meldungen werden erwartet

13.03.2000
Stressgen kaufen
Global Biotech Investing

Die Spezialisten von Global Biotech Investing empfehlen derzeit die kanadische Aktie Stressgen (WKN 901062) zum Kauf.

Stressgen sei eine kanadische Krebsforschungsgesellschaft, welche durch Stress-Signale oder Hitzeschock Proteine zur Bekämpfung entarteter Krebszellen entwickele. Das Hauptprodukt sei HspE7.

Analysten des Investmenthauses Nesbitt Burns aus Toronto rechnen mit einer Kursverdreifachung bei Stressgen. Experten würden sensationelle News in den kommenden Wochen erwarten.

ANTIGENICS ein Unternehmen, welches in ähnlichen Bereichen arbeite, habe eine sieben mal so hohe Marktkapitalisierung. Nesbitt Burns sehe eine faire Bewertung bei CAD von 760 Mio., was eine Kurs von CAD 19 rechtfertigen würde. Kaufaufträge müssten jedoch wegen der Marktenge streng limitiert werden.



Aufwärtstrend ist vollkommen intakt, im Gegensatzt zu manch anderen Biotechs.

Die 6 Euro wurden schon einige Male getestet. >> Gilt als massiver Wiederstand

STRONG BUY Kursziel 21 Euro
---

[mailthomas_1999]

Habe gerade bei OnVista nachgeschaut:

Immune Response hat auf jetzigem Kursniveau von 18,10 EUR eine Marktkapitaliesierung von nur 277 Mio EUR.

Ich würde sagen: Kaufen, was das Konto hält!!!!

[109]

Genau jetzt schon über 9.000,000 Stücke. Das geht ab.